Antibody-based HIV-1 vaccines: recent developments and future directions

doi:10.1371/journal.pmed.0040348

. 2007 Dec;4(12):e348.

doi: 10.1371/journal.pmed.0040348.

Antibody-based HIV-1 vaccines: recent developments and future directions

David Montefiori¹, Quentin Sattentau, Jorge Flores, José Esparza, John Mascola; Working Group convened by the Global HIV Vaccine Enterprise

Affiliations

PMID: 18052607
PMCID: PMC2100141
DOI: 10.1371/journal.pmed.0040348

Antibody-based HIV-1 vaccines: recent developments and future directions

David Montefiori et al. PLoS Med. 2007 Dec.

. 2007 Dec;4(12):e348.

doi: 10.1371/journal.pmed.0040348.

Authors

David Montefiori¹, Quentin Sattentau, Jorge Flores, José Esparza, John Mascola; Working Group convened by the Global HIV Vaccine Enterprise

Affiliation

¹ Duke University Medical Center, Durham, North Carolina, United States of America. monte@duke.edu

PMID: 18052607
PMCID: PMC2100141
DOI: 10.1371/journal.pmed.0040348

Abstract

The authors discuss humoral immune responses to HIV and approaches to designing vaccines that induce viral neutralizing and other potentially protective antibodies.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Cited by

International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.
Ozaki DA, Gao H, Todd CA, Greene KM, Montefiori DC, Sarzotti-Kelsoe M. Ozaki DA, et al. PLoS One. 2012;7(1):e30963. doi: 10.1371/journal.pone.0030963. Epub 2012 Jan 27. PLoS One. 2012. PMID: 22303476 Free PMC article.
Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.
Nkolola JP, Peng H, Settembre EC, Freeman M, Grandpre LE, Devoy C, Lynch DM, La Porte A, Simmons NL, Bradley R, Montefiori DC, Seaman MS, Chen B, Barouch DH. Nkolola JP, et al. J Virol. 2010 Apr;84(7):3270-9. doi: 10.1128/JVI.02252-09. Epub 2010 Jan 6. J Virol. 2010. PMID: 20053749 Free PMC article.
Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection.
Symmonds J, Gaufin T, Xu C, Raehtz KD, Ribeiro RM, Pandrea I, Apetrei C. Symmonds J, et al. Viruses. 2024 Jun 17;16(6):972. doi: 10.3390/v16060972. Viruses. 2024. PMID: 38932264 Free PMC article. Review.
Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.
Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, Conway JA, Wieczorek L, Brown B, Polonis V, West JT, Montefiori DC, Kappes JC, Ochsenbauer C. Edmonds TG, et al. Virology. 2010 Dec 5;408(1):1-13. doi: 10.1016/j.virol.2010.08.028. Epub 2010 Sep 21. Virology. 2010. PMID: 20863545 Free PMC article.
Genetic imprint of vaccination on simian/human immunodeficiency virus type 1 transmitted viral genomes in rhesus macaques.
Varela M, Verschoor E, Lai RP, Hughes J, Mooj P, McKinley TJ, Fitzmaurice TJ, Landskron L, Willett BJ, Frost SD, Bogers WM, Heeney JL. Varela M, et al. PLoS One. 2013 Aug 14;8(8):e70814. doi: 10.1371/journal.pone.0070814. eCollection 2013. PLoS One. 2013. PMID: 23967111 Free PMC article.

See all "Cited by" articles

References

1. Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. The Global HIV/AIDS Vaccine Enterprise: Scientific strategic plan. PLoS Med. 2005;2:e25. doi: 10.1371/journal.pmed.0020025. - DOI - PMC - PubMed
1. Mascola JR, D'Souza P, Gilbert P, Hahn B, Haigwood NL, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol. 2005;79:10103–10107. - PMC - PubMed
1. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science. 1998;280:1884–1888. - PubMed
1. Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies. 2005;14:101–113. - PMC - PubMed
1. Moore PL, Crooks ET, Porter L, Porter L, Zhu P, et al. The nature of non-functional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006;80:2515–2528. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information

[1] Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. The Global HIV/AIDS Vaccine Enterprise: Scientific strategic plan. PLoS Med. 2005;2:e25. doi: 10.1371/journal.pmed.0020025. - DOI - PMC - PubMed

[2] Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. The Global HIV/AIDS Vaccine Enterprise: Scientific strategic plan. PLoS Med. 2005;2:e25. doi: 10.1371/journal.pmed.0020025. - DOI - PMC - PubMed

[3] Mascola JR, D'Souza P, Gilbert P, Hahn B, Haigwood NL, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol. 2005;79:10103–10107. - PMC - PubMed

[4] Mascola JR, D'Souza P, Gilbert P, Hahn B, Haigwood NL, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol. 2005;79:10103–10107. - PMC - PubMed

[5] Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science. 1998;280:1884–1888. - PubMed

[6] Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science. 1998;280:1884–1888. - PubMed

[7] Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies. 2005;14:101–113. - PMC - PubMed

[8] Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, et al. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum Antibodies. 2005;14:101–113. - PMC - PubMed

[9] Moore PL, Crooks ET, Porter L, Porter L, Zhu P, et al. The nature of non-functional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006;80:2515–2528. - PMC - PubMed

[10] Moore PL, Crooks ET, Porter L, Porter L, Zhu P, et al. The nature of non-functional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006;80:2515–2528. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Antibody-based HIV-1 vaccines: recent developments and future directions

Affiliation

Antibody-based HIV-1 vaccines: recent developments and future directions

Authors

Affiliation

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical